Northwest & Ethical Investments L.P. Has $31.91 Million Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Northwest & Ethical Investments L.P. increased its stake in Gilead Sciences by 16.6% during the first quarter, acquiring an additional 40,620 shares, bringing its total holdings to 284,815 shares valued at $31,914,000.
• Institutional investors now own 83.67% of Gilead’s stock, with several firms, including Nuveen LLC and GAMMA Investing LLC, making substantial purchases during the first quarter.
• Gilead Sciences reported a quarterly EPS of $2.01, exceeding estimates, and announced a $0.79 dividend scheduled for payment on September 29th, yielding 2.7%.

Northwest & Ethical Investments L.P. boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.6% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 284,815 shares of the biopharmaceutical company's stock after buying an additional 40,620 shares during the quarter. Gilead Sciences makes up about 0.9% of Northwest & Ethical Investments L.P.'s holdings, making the stock its 22nd biggest position. Northwest & Ethical Investments L.P.'s holdings in Gilead Sciences were worth $31,914,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Gilead Sciences by 15.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,234,672 shares of the biopharmaceutical company's stock valued at $1,130,117,000 after purchasing an additional 1,605,730 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Gilead Sciences by 30.1% during the 4th quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock valued at $801,655,000 after purchasing an additional 2,005,863 shares in the last quarter. Finally, Nuveen LLC bought a new position in shares of Gilead Sciences during the 1st quarter valued at $620,415,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

GILD has been the topic of a number of recent research reports. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Finally, Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $115.39.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the sale, the chief executive officer owned 605,725 shares in the company, valued at approximately $69,016,306.50. This trade represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 110,000 shares of company stock valued at $12,349,790 in the last 90 days. Insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.75 on Wednesday, hitting $118.73. 5,623,636 shares of the company were exchanged, compared to its average volume of 8,312,371. The company's 50 day moving average price is $112.14 and its two-hundred day moving average price is $108.71. Gilead Sciences, Inc. has a one year low of $74.80 and a one year high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market capitalization of $147.32 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 0.72 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same period in the previous year, the business earned $2.01 EPS. The firm's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.